Global /Japan /Healthcare /Biotechnology /4884

Kringle Pharma, Inc.

4884

• TSE: 4884 • Delayed

461JPY -4.8%

2.88 USD

As of 6 June 2026, Kringle Pharma, Inc. has a market cap of $22.23M USD, ranking #36391 globally and #3494 in Japan. It ranks #3270 in the Healthcare sector, and #638 in the Biotechnology industry.

Global Rank

36391

Country Rank

3494

Sector Rank

3270

Industry Rank

638

Key Stats

Market Cap

$22.23MUSD

3.56B JPY

Enterprise Value

$16.69MUSD

2.67B JPY

Revenue (TTM)

$453.82KUSD

72.62M JPY

Net Income (TTM)

-$5.66MUSD

-905.42M JPY

PS Ratio

49.0

PB Ratio

2.9

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Biotechnology

CEO

Kiichi Adachi open_in_new

Employees

Founded

2001

Website

kringle-pharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.8%	-17%	17%	17%	7.5%	19%	-44%	-46%	-50%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4884 クリングルファーマ株式会社 Ordinary Shares ISIN: JP3270790003 Shares Out.: Shares Outstanding: 8.383M¹ Shares Float: 6.904M² TV: TradingView: TSE: 4884 SA: Stock Analysis: TYO: 4884 YF: Yahoo Finance: 4884.T GF: Google Finance: TYO: 4884 BA: Barron's: 4884 MS: Morningstar: XTKS: 4884	461 JPY	TV: TradingView: TSE: 4884 SA: Stock Analysis: TYO: 4884 YF: Yahoo Finance: 4884.T GF: Google Finance: TYO: 4884 BA: Barron's: 4884 MS: Morningstar: XTKS: 4884

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Kringle Pharma, Inc.

Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.

Similar Companies

Industry: Biotechnology (Japan)

Name	Market Cap (USD) diff.	PE	Country
GNI Group Ltd. TSE: 2160	$1.02B 162.8B JPY 4K%	-	Japan
PeptiDream Inc. TSE: 4587	$929.38M 148.73B JPY 4K%	-	Japan
Oncolys BioPharma Inc. TSE: 4588	$526.3M 84.22B JPY 2K%	-	Japan
Cuorips Inc. TSE: 4894	$349.85M 55.99B JPY 1K%	-	Japan
Innovacell Inc. TSE: 504A	$169.94M 27.19B JPY 665%	-	Japan
Stella Pharma Corp. TSE: 4888	$113.62M 18.18B JPY 411%	-	Japan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 821K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 719K%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 216K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 200K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 193K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 192K%	37.2	Switzerland

chevron_leftBack